Full Text
PND38 Cost Minimization Analysis of Fingolimod Versus Natalizumab in the Second-Line Treatment of Remittent-Recurrent Multiple Sclerosis

Abstract

Authors

C. Crespo G. Izquierdo A. García-Ruiz M. Granell M. Brosa

Back to Volume 15, Issue 7
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×